Market News & Trends
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) recently announced the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating…
Sever Pharma Solutions Celebrates 50 years of Pharmaceutical Innovation
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release drug delivery systems for high-potent drugs, is proud to celebrate…
Azalea Therapeutics Presents New Preclinical Data Demonstrating Robust In Vivo Generation of TRAC-CAR T Cells Using Enveloped Delivery Vehicles
Azalea Therapeutics, Inc. recently announced new preclinical data demonstrating robust in vivo generation of functional TRAC-CAR T cells using its proprietary Enveloped Delivery Vehicle (EDV) technology.…
BriaCell & Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
BriaCell Therapeutics Corp. recently announced its subsidiary, BriaPro Therapeutics Corp., has initiated a research collaboration with Receptor.AI, an AI-driven drug discovery company, to design anti-cancer…
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
Oncotelic Therapeutics, Inc. recently announced its joint venture partner, GMP Bio, has completed an independent third-party valuation of its drug development pipeline. The preliminary valuation,…
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
FibroBiologics, Inc. recently announced it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial…
Novartis Announces Plans to Build Flagship Manufacturing Hub in North Carolina
Novartis recently announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is…
Gattefossé Celebrates 20 Years in China; Two Decades of Growth, Partnership & Innovation
Gattefossé, the French specialist in lipid chemistry and plant-based ingredients for the personal care and pharmaceutical industries, celebrates 20 years of presence in China. On…
Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients With Lymphatic Malformations
Protara Therapeutics, Inc. recently announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company’s investigational cell-based therapy,…
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Ltd. recently announced the successful initiation of the Company's Phase 2 clinical study with dosing of the first participant in Canada. The trial…
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics NV recently announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129),…
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
One-carbon Therapeutics AB recently announced the first subject has been successfully dosed in its ODIN Phase 1/2 clinical trial (NCT07151040) evaluating TH9619, a first-in-class MTHFD1/2…
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating…
LifeMD to Offer Market-Leading Pricing for GLP-1 Medications Wegovy & Ozempic in Continued Collaboration With Novo Nordisk
LifeMD, Inc. recently announced a new, lower cash-pay price for GLP-1 medications, Wegovy and Ozempic, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will…
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Halda Therapeutics recently announced it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in…
Azurity Pharmaceuticals & Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. Ronald Scarboro,…
AEON Biopharma Reports Positive & Robust Biosimilarity Results: Identical Amino Acid Sequence & Highly Similar Functional Analysis Data
AEON Biopharma, Inc., a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, recently announced…
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech, Inc. recently provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented…
Adagene Announces Licensing Agreement With Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology
Adagene Inc. and Third Arc Bio, Inc. recently announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate…
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension to the FDA
Cereno Scientific, an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, recently announced the submission of…
